Inside Out: C-reactive Protein (CRP) as Clinical Biomarker with Lipid Profile and Lactate Dehydrogenase in Metabolic Syndrome

Authors

Rubina Ghani
Uzma Naseeb
Erum Afaq
Sassi Kanwal BAHRIA UNIVERSITY OF MEDICAL AND DENTAL COLLEGE
Muzna Shah
Zeelaf Shahid

DOI:

https://doi.org/10.51273/esc25.251321130

Keywords:

C-reactive protein, lactate dehydrogenase, metabolic syndrome, body mass index, Basal metabolic rate

Abstract

Abstract
Objective: To evaluate and compare the levels of C-reactive protein (CRP) and its correlation with lactate
dehydrogenase (LDH) and abnormal lipid profiles in patients with metabolic syndrome versus healthy
control.
Material and Methods: This was a case-control study and was conducted at the pathology laboratory of
Jinnah Medical and Dental College from May 27, 2023 to December 27, 2023, receiving approval from the
Ethical Review Committee of Sohail University in Karachi. Involved 300 participants, comprising 150
individuals diagnosed with metabolic syndrome and 150 healthy controls, representing the elderly age group
and both genders. Following the acquisition of informed consent, demographic information and
anthropometric measurements were documented, and blood samples were collected after an overnight fast to
assess fasting blood sugar, lipid profiles, lactate dehydrogenase (LDH), and C-reactive protein (CRP)
utilizing Bioscience and Oet-N10 kits, respectively.
Results: The results obtained in this study were compared between metabolic syndrome and control samples.
Using the students't-test, the positive correlation was found between CRP and LDH in patients with
metabolic syndrome with dyslipidemia as compared to healthy controls. The statistically significant
difference was noted in BMI, WC, HC and WHR ratio between metabolic syndrome patients and controls,
Conclusion: This current study found that individuals with metabolic syndrome had higher basal metabolic
rates, along with elevated CRP and LDH levels, which were independently associated with metabolic
syndrome; Clinical monitoring and public health interventions are needed to reduce metabolic syndrome and
its associated complications.
Keywords: C-reactive protein (CRP), lactate dehydrogenase (LDH), metabolic syndrome, body mass index
(BMI), Basal metabolic rate (BMR)
How to cite: Inside Out: C-reactive Protein (crp) as Clinical Biomarker with Lipid Profile and Lactate Dehydrogenase
in Metabolic Syndrome Comparison of the Efficacy of Gabapentin with Loratadine in Patients of Chronic Kidney
Disease with Uremic Pruritus. Esculapio - JSIMS 2025;21(01): 168-173
DOI: https://doi.org/10.51273/esc25.251321130

References

Aguilar-Salinas CA, Viveros-Ruiz T. Recent

advances in managing/understanding the metabolic

syndrome. F1000Research. 2019;8. doi:

12688/f1000research.17122.1.

Wang Z, Wang B, Li X, Zhang S, Wu S, Xia Y.

Metabolic syndrome, high-sensitivity C-reactive

protein levels and the risk of new-onset atrial

fibrillation: results from the Kailuan study. Nutrition,

Metabolism and Cardiovascular Diseases. 2021 Jan

;31(1):102-9. https://doi.org/10.1016/-j.numecd.

06.026.

Syed Mehmood ul Hassan, Rafique Malik B, Ali Y,

Asghar U, Qadir A, M. Tayyab R. Obstructive Sleep

Apnea in patients with Metabolic syndrome - A

hospital Based Cross-Sectional Survey. Esculapio -

JSIMS [Internet]. 2023 Jul. 30 [cited 2025 Feb.

;16(1):52-6., DOI: https://doi.org/10.51273/

esc20.716113.

Pan H, Yan D, Xu M, Li F, Ren M, Zhang J, Wu M.

Interaction between lactate and uric acid is associated

with a higher prevalence of metabolic syndrome: a

community-based study. Experimental and Clinical

Endocrinology & Diabetes. 2019 Sep;127(08):557

DOI: 10.1055/a-0672-0908.

Hummayun H, Naz T, Waheed SS. Metabolic

Syndrome and Hyperandrogenemia in Polycystic

Ovarian Syndrome. Esculapio - JSIMS.

;18(02):169-173. Available from: https://

doi.org/10.51273/esc22.25182131-3.

Boncler M, Wu Y, Watala C. The multiple faces of C

reactive protein—physiological and pathop

hysiological implications in cardiovascular disease.

Molecules. 2019 May 30;24(11):2062.

doi.org/10.3390/molecules24112062.

Jimenez RV, Szalai AJ. Therapeutic lowering of C

reactive protein. Frontiers in immunology. 2021 Jan

;11:619564. doi.org/10.3389/-fimmu.20

619564.

Hoyas I, Leon-Sanz M. Nutritional challenges in

metabolic syndrome. Journal of clinical medicine.

Aug 24;8(9):1301. doi.org/10.3390/

jcm8091301.

Silveira Rossi JL, Barbalho SM, Reverete de Araujo

R, Bechara MD, Sloan KP, Sloan LA. Metabolic

syndrome and cardiovascular diseases: Going

beyond traditional risk factors. Diabetes/metabolism

research and reviews. 2022 Mar;38(3):e3502.

doi.org/10.1002/dmrr.3502.

Villasante Fricke AC, Iacobellis G. Epicardial

adipose tissue: clinical biomarker of cardio

metabolic risk. International journal of molecular

sciences. 2019 Nov 28;20(23):5989. doi.org/10

.3390/ijms20235989.

Münzel T, Hahad O, Sørensen M, Lelieveld J, Duerr

GD, Nieuwenhuijsen M, Daiber A. Environmental

risk factors and cardiovascular diseases: a

comprehensive expert review. Cardiovascular

research. 2022 Oct 1;118(14):2880-902.

https://doi.org/10.1093/cvr/cvab316.

Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou

Zerdan M, Bouferraa Y, Assi HI. Metabolic

syndrome: updates on pathophysiology and

management in 2021. International journal of

molecular sciences. 2022 Jan 12;23(2):786.

doi.org/10.3390/ijms23020786.

Kumari R, Kumar S, Kant R. An update on metabolic

syndrome: Metabolic risk markers and adipokines in

the development of metabolic syndrome. Diabetes &

Metabolic Syndrome: Clinical Research & Reviews.

Jul 1;13(4):2409-17. doi.org/10.1016/

j.dsx.2019.06.005.

Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C,

Toledo E, Moreno-Iribas C. Risk for cardiovascular

disease associated with metabolic syndrome and its

components: a 13-year prospective study in the

RIVANA cohort. Cardiovascular diabetology. 2020

Dec;19:1-4. doi.org/10.1186/s12933-020-01166-6.

Fan W, Huang Y, Zheng H, Li S, Li Z, Yuan L, Cheng

X, He C, Sun J. Ginsenosides for the treatment of

metabolic syndrome and cardiovascular diseases:

Pharmacology and mechanisms. Biomedicine &

Pharmacotherapy. 2020 Dec 1;132:110915.

https://doi.org/10.1016/j.biopha.2020.110915.

Lee M.K, Han K, Kim M.K, Koh E.S, Kim E.S, Nam

G, E, Kwon H.S. Changes in metabolic syndrome and

its components and the risk of type 2 diabetes: a

nationwide cohort study. Sci Rep, 2020, 10(1):2313.

doi:10.1038/s41598-020-59203-z.

Zeller J, Bogner B, McFadyen JD, Kiefer J, Braig D,

Pietersz G, Krippner G, Nero TL, Morton CJ, Shing

KC, Parker MW. Transitional changes in the structure

of C-reactive protein create highly pro-inflammatory

molecules: Therapeutic implications for

cardiovascular diseases. Pharmacology &

Therapeutics. 2022 Jul 1;235:108165.

https://doi.org/10.1016/j.pharmthera.2022.108165

Rifai N. High-sensitivity C-reactive protein: a useful

marker for cardiovascular disease risk prediction and

the metabolic syndrome. Clinical chemistry. 2005

Mar 1;51(3):504-5. https://doi.org/10.1373/

clinchem.2004.044990

Chang SH, Chang YY, Wu LY. Gender differences in

lifestyle and risk factors of metabolic syndrome: Do

women have better health habits than men?. Journal

of clinical nursing. 2019 Jun;28(11-12):2225-34.

doi.org/10.1111/jocn.14824.

Suwała S, Junik R. Body mass index and waist

circumference as predictors of above-average

increased cardiovascular risk assessed by the

SCORE2 and SCORE2-OP calculators and the

proposition of new optimal cut-off values: cross

sectional single-center study. J Clin Med. 2024 Mar

;13(7):1931. doi:10.3390/jcm13071931. PMID:

; PMCID: PMC11012561.

Primo D, Izaola O, de Luis DA. Triglyceride-glucose

index cutoff point is an accurate marker for predicting

the prevalence of metabolic syndrome in obese

Caucasian subjects. Ann Nutr Metab.

;79(2):238-245. doi:10.1159/000530144.

Tewari A, Kumar G, Maheshwari A, Tewari V, Tewari

J. Comparative evaluation of waist-to-height ratio

and BMI in predicting adverse cardiovascular

outcome in people with diabetes: a systematic review.

Cureus. 2023 May 9;15(5)doi: 10.7759/

cureus.38801. PMID: 37303408; PMCID:

PMC10250251.

Ramírez-Manent JI, Jover AM, Martinez CS, Tomás

Gil P, Martí-Lliteras P, López-González ÁA. Waist

Circumference Is an Essential Factor in Predicting

Insulin Resistance and Early Detection of Metabolic

Syndrome in Adults. Nutrients. 2023 Jan

;15(2):257. doi: 10.3390/nu15020257. PMID:

; PMCID: PMC9861022.

Paredes S, Fonseca L, Ribeiro L, et al. Novel and

traditional lipid profiles in Metabolic Syndrome

reveal a high atherogenicity. Sci Rep. 2019;9:11792.

doi:10.1038/s41598-019-48120-5.

Gesteiro E, Megía A, Guadalupe-Grau A, Fernandez

Veledo S, Vendrell J, González-Gross M. Early

identification of metabolic syndrome risk: A review

of reviews and proposal for defining pre-metabolic

syndrome status. Syst Rev Meta-Anal.

;12(5):120-132. doi:10.1016/-j.srma.2021

.05.003. **C-Reactive Protein and Lactate

Dehydrogenase: Risk Markers in Metabolic

Syndrome vs. Healthy Controls

Downloads

Published

2025-03-31

How to Cite

Rubina Ghani, Uzma Naseeb, Erum Afaq, Sassi Kanwal, Muzna Shah, Zeelaf Shahid. Inside Out: C-reactive Protein (CRP) as Clinical Biomarker with Lipid Profile and Lactate Dehydrogenase in Metabolic Syndrome. Esculapio - JSIMS [Internet]. 2025 Mar. 31 [cited 2025 May 13];21(1):168-73. Available from: https://esculapio.pk/journal/index.php/journal-files/article/view/1231